

Bevacizumab – Fact Sheet

Molecule


Bevacizumab (Avastin®) is a typical humanized monoclonal IgG1 / kappa antibody comprised of a tetramer of two heavy and two light chains with one N-glycosylation site per heavy chain.

Mode of Action

Bevacizumab inhibits angiogenesis (formation of new blood vessels) by blocking the interaction of Vascular Endothelial Growth Factor A (VEGF-A) with its receptors, VEGF receptor-1 or VEGF receptor-2. Bevacizumab can therefore also slow the growth of new blood vessels in tumors.

Indication

Bevacizumab is indicated for various cancers including metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and also for a few glioblastomas.



Patent Situation

Bevacizumab patents expired in US (2019) and will expire in EU (2022). Roche as owner of the originator will

defend these dates and all biosimilar developments in late stage will have to wait for market entry in EU until expiration of the patents.

Market and Competitive Field

The originator product, Roche's Avastin® was approved by FDA in 2004 and by EMA in 2005. Avastin® had sales of 4.58 and 2.96 billion in 2020 and 2021, respectively, obviously decreasing due to biosimilars. Mvasi® from Amgen had in 2021 increased sales of already 1.08 billion € (up from 0.659 billion € in 2020). Pfizer also started sales of Zirabev® and in developing countries, non-originator biologicals are marketed as well.

VelaLabs Portfolio

		Bevacizumab
		Avastin®, Mvasi®, Zirabev®
Clone selection/ comparability		
HPLC	Separation based on size (SE-HPLC)	
	Separation based on hydrophobicity (RP-HPLC)	
	Detection of charge variants (CEX-HPLC)	
Binding	Binding to cell surface expressed target (Flow cytometry)	n.a.
	Binding to soluble target (ELISA)	
	Binding to specific antibody or antigen (SPR-BIACORE, ELISA)	
	Affinity/ kinetic to recombinant target (SPR-BIACORE)	
Effector function	Binding to C1q, ¹ CDC surrogate (ELISA)	
	Affinity to recombinant Fc-receptors (SPR-BIACORE)	
	Reporter gene assays, ² ADCC surrogate (Luminescence)	n.a.
	¹ CDC (Flow cytometry)	n.a.
	² ADCC (DELFI, Fluorescence)	n.a.
	Additional bioassays (Luminescence, fluorescence)	Anti-proliferation
Gly	Glyco-pattern with Lectin Microarray (45 different lectins)	
(Pre)clinical application		
Clinics	Pharmacokinetics – PK (ECL, ELISA)	
	Pharmacodynamics – PD (ECL, ELISA, flow cytometry, bioassay)	
	Immunogenicity - ³ ADAs (ECL, Biacore, ELISA, neutr. assay)	

¹CDC = Complement Dependent Cytotoxicity
²ADCC = Antibody Dependent Cellular Cytotoxicity
³ADA = Anti-Drug Antibody

	Vela portfolio
	n.a. = not applicable

If you are interested in the full version including patent and originator data please contact us: velabd@vela-labs.at